Protective immunity by an engineered DNA vaccine for Mayaro virus

Hyeree Choi, Sagar B. Kudchodkar, Emma L. Reuschel, Kanika Asija, Piyush Borole, Michelle Ho, Krzysztof Wojtak, Charles Reed, Stephanie Ramos, Nathen E. Bopp, Patricia Aguilar, Scott Weaver, J. Joseph Kim, Laurent Humeau, Pablo Tebas, David B. Weiner, Kar Muthumani

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Mayaro virus (MAYV) of the genus alphavirus is a mosquito-transmitted emerging infectious disease that causes an acute febrile illness, rash, headaches, and nausea that may turn into incapacitating, persistent arthralgias in some victims. Since its discovery in Trinidad in 1954, cases of MAYV infection have largely been confined there and to the northern countries of South America, but recently, MAYV cases have been reported in some island nations in the Caribbean Sea. Accompanying these reports is evidence that new vectors, including Aedes spp. mosquitos, recently implicated in the global spread of Zika and chikungunya viruses, are competent for MAYV transmission, which, if true, could facilitate the spread of MAYV beyond its current range. Despite its status as an emerging virus, there are no licensed vaccines to prevent MAYV infection nor therapeutics to treat it. Here, we describe the development and testing of a novel DNA vaccine, scMAYV-E, that encodes a synthetically-designed consensus MAYV envelope sequence. In vivo electroporation-enhanced immunization of mice with this vaccine induced potent humoral responses including neutralizing antibodies as well as robust T-cell responses to multiple epitopes in the MAYV envelope. Importantly, these scMAYV-E-induced immune responses protected susceptible mice from morbidity and mortality following a MAYV challenge.

Original languageEnglish (US)
Pages (from-to)e0007042
JournalPLoS neglected tropical diseases
Volume13
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

DNA Vaccines
Immunity
Viruses
Virus Diseases
Culicidae
Vaccines
Chikungunya virus
Emerging Communicable Diseases
Trinidad and Tobago
Alphavirus
Electroporation
South America
Aedes
Arthralgia
Exanthema
Neutralizing Antibodies
Islands
Nausea
Headache
Epitopes

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Choi, H., Kudchodkar, S. B., Reuschel, E. L., Asija, K., Borole, P., Ho, M., ... Muthumani, K. (2019). Protective immunity by an engineered DNA vaccine for Mayaro virus. PLoS neglected tropical diseases, 13(2), e0007042. https://doi.org/10.1371/journal.pntd.0007042

Protective immunity by an engineered DNA vaccine for Mayaro virus. / Choi, Hyeree; Kudchodkar, Sagar B.; Reuschel, Emma L.; Asija, Kanika; Borole, Piyush; Ho, Michelle; Wojtak, Krzysztof; Reed, Charles; Ramos, Stephanie; Bopp, Nathen E.; Aguilar, Patricia; Weaver, Scott; Kim, J. Joseph; Humeau, Laurent; Tebas, Pablo; Weiner, David B.; Muthumani, Kar.

In: PLoS neglected tropical diseases, Vol. 13, No. 2, 01.02.2019, p. e0007042.

Research output: Contribution to journalArticle

Choi, H, Kudchodkar, SB, Reuschel, EL, Asija, K, Borole, P, Ho, M, Wojtak, K, Reed, C, Ramos, S, Bopp, NE, Aguilar, P, Weaver, S, Kim, JJ, Humeau, L, Tebas, P, Weiner, DB & Muthumani, K 2019, 'Protective immunity by an engineered DNA vaccine for Mayaro virus', PLoS neglected tropical diseases, vol. 13, no. 2, pp. e0007042. https://doi.org/10.1371/journal.pntd.0007042
Choi H, Kudchodkar SB, Reuschel EL, Asija K, Borole P, Ho M et al. Protective immunity by an engineered DNA vaccine for Mayaro virus. PLoS neglected tropical diseases. 2019 Feb 1;13(2):e0007042. https://doi.org/10.1371/journal.pntd.0007042
Choi, Hyeree ; Kudchodkar, Sagar B. ; Reuschel, Emma L. ; Asija, Kanika ; Borole, Piyush ; Ho, Michelle ; Wojtak, Krzysztof ; Reed, Charles ; Ramos, Stephanie ; Bopp, Nathen E. ; Aguilar, Patricia ; Weaver, Scott ; Kim, J. Joseph ; Humeau, Laurent ; Tebas, Pablo ; Weiner, David B. ; Muthumani, Kar. / Protective immunity by an engineered DNA vaccine for Mayaro virus. In: PLoS neglected tropical diseases. 2019 ; Vol. 13, No. 2. pp. e0007042.
@article{bba0e28a2f0a4233bb193be3475f6247,
title = "Protective immunity by an engineered DNA vaccine for Mayaro virus",
abstract = "Mayaro virus (MAYV) of the genus alphavirus is a mosquito-transmitted emerging infectious disease that causes an acute febrile illness, rash, headaches, and nausea that may turn into incapacitating, persistent arthralgias in some victims. Since its discovery in Trinidad in 1954, cases of MAYV infection have largely been confined there and to the northern countries of South America, but recently, MAYV cases have been reported in some island nations in the Caribbean Sea. Accompanying these reports is evidence that new vectors, including Aedes spp. mosquitos, recently implicated in the global spread of Zika and chikungunya viruses, are competent for MAYV transmission, which, if true, could facilitate the spread of MAYV beyond its current range. Despite its status as an emerging virus, there are no licensed vaccines to prevent MAYV infection nor therapeutics to treat it. Here, we describe the development and testing of a novel DNA vaccine, scMAYV-E, that encodes a synthetically-designed consensus MAYV envelope sequence. In vivo electroporation-enhanced immunization of mice with this vaccine induced potent humoral responses including neutralizing antibodies as well as robust T-cell responses to multiple epitopes in the MAYV envelope. Importantly, these scMAYV-E-induced immune responses protected susceptible mice from morbidity and mortality following a MAYV challenge.",
author = "Hyeree Choi and Kudchodkar, {Sagar B.} and Reuschel, {Emma L.} and Kanika Asija and Piyush Borole and Michelle Ho and Krzysztof Wojtak and Charles Reed and Stephanie Ramos and Bopp, {Nathen E.} and Patricia Aguilar and Scott Weaver and Kim, {J. Joseph} and Laurent Humeau and Pablo Tebas and Weiner, {David B.} and Kar Muthumani",
year = "2019",
month = "2",
day = "1",
doi = "10.1371/journal.pntd.0007042",
language = "English (US)",
volume = "13",
pages = "e0007042",
journal = "PLoS Neglected Tropical Diseases",
issn = "1935-2727",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Protective immunity by an engineered DNA vaccine for Mayaro virus

AU - Choi, Hyeree

AU - Kudchodkar, Sagar B.

AU - Reuschel, Emma L.

AU - Asija, Kanika

AU - Borole, Piyush

AU - Ho, Michelle

AU - Wojtak, Krzysztof

AU - Reed, Charles

AU - Ramos, Stephanie

AU - Bopp, Nathen E.

AU - Aguilar, Patricia

AU - Weaver, Scott

AU - Kim, J. Joseph

AU - Humeau, Laurent

AU - Tebas, Pablo

AU - Weiner, David B.

AU - Muthumani, Kar

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Mayaro virus (MAYV) of the genus alphavirus is a mosquito-transmitted emerging infectious disease that causes an acute febrile illness, rash, headaches, and nausea that may turn into incapacitating, persistent arthralgias in some victims. Since its discovery in Trinidad in 1954, cases of MAYV infection have largely been confined there and to the northern countries of South America, but recently, MAYV cases have been reported in some island nations in the Caribbean Sea. Accompanying these reports is evidence that new vectors, including Aedes spp. mosquitos, recently implicated in the global spread of Zika and chikungunya viruses, are competent for MAYV transmission, which, if true, could facilitate the spread of MAYV beyond its current range. Despite its status as an emerging virus, there are no licensed vaccines to prevent MAYV infection nor therapeutics to treat it. Here, we describe the development and testing of a novel DNA vaccine, scMAYV-E, that encodes a synthetically-designed consensus MAYV envelope sequence. In vivo electroporation-enhanced immunization of mice with this vaccine induced potent humoral responses including neutralizing antibodies as well as robust T-cell responses to multiple epitopes in the MAYV envelope. Importantly, these scMAYV-E-induced immune responses protected susceptible mice from morbidity and mortality following a MAYV challenge.

AB - Mayaro virus (MAYV) of the genus alphavirus is a mosquito-transmitted emerging infectious disease that causes an acute febrile illness, rash, headaches, and nausea that may turn into incapacitating, persistent arthralgias in some victims. Since its discovery in Trinidad in 1954, cases of MAYV infection have largely been confined there and to the northern countries of South America, but recently, MAYV cases have been reported in some island nations in the Caribbean Sea. Accompanying these reports is evidence that new vectors, including Aedes spp. mosquitos, recently implicated in the global spread of Zika and chikungunya viruses, are competent for MAYV transmission, which, if true, could facilitate the spread of MAYV beyond its current range. Despite its status as an emerging virus, there are no licensed vaccines to prevent MAYV infection nor therapeutics to treat it. Here, we describe the development and testing of a novel DNA vaccine, scMAYV-E, that encodes a synthetically-designed consensus MAYV envelope sequence. In vivo electroporation-enhanced immunization of mice with this vaccine induced potent humoral responses including neutralizing antibodies as well as robust T-cell responses to multiple epitopes in the MAYV envelope. Importantly, these scMAYV-E-induced immune responses protected susceptible mice from morbidity and mortality following a MAYV challenge.

UR - http://www.scopus.com/inward/record.url?scp=85061244979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061244979&partnerID=8YFLogxK

U2 - 10.1371/journal.pntd.0007042

DO - 10.1371/journal.pntd.0007042

M3 - Article

C2 - 30730897

AN - SCOPUS:85061244979

VL - 13

SP - e0007042

JO - PLoS Neglected Tropical Diseases

JF - PLoS Neglected Tropical Diseases

SN - 1935-2727

IS - 2

ER -